Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

Inclusion criteria

• Men and women aged 18-75 years old
• Body mass index (BMI) ≥18.0 and <50.0 kg/m2 at the screening visit
• Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit
• Diagnosed with chronic kidney disease, and the estimated glomerular filtration rate (eGFR) was ≥30 and <90 mL/min/1.73 m2 calculated using the CKD-EPI formula at the screening visit
• Urinary albumin/creatinine ratio (UACR) was ≥300 and <3000 mg/g for at least 2 times on different days detected by the local laboratory; at the screening visit
• HbA1c <9.0% at the screening visit

Exclusion criteria

• A known or suspected allergy to the investigational drug or its components or excipients;
• Receive a potent inhibitor/inducer of cytochrome P450 3A4 (CYP3A4) within 7 days prior to screening;
• Within 4 weeks before screening, the following drugs could not maintain the stable regimen: diabetes drugs, hypertension drugs, non-steroidal anti-inflammatory drugs, endothelin receptor antagonists;
• Receive SGLT-2 or SGLT-1/2 inhibitors within 4 weeks before screening
• Received glucagon-like peptide-1 receptor agonist (GLP-1RA) within 8 weeks before screening
• Received systemic glucocorticoid therapy within 3 months before screening
• Received immunosuppressive drugs or biological agents
• Received any other study drug treatment within 3 months or 5 half-lives prior to screening
• Severe hypertension that was not controlled at screening visit or random visit (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), or systolic blood pressure <90 mmHg
• Have urinary tract infection or/and genital infection at the screening visit or random visit, or have a history of repeated urinary tract infection or/and genital infection
• Diagnosed or suspected polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, acute glomerulonephritis, bilateral renal artery stenosis;
• Acute kidney injury or dialysis treatment within 6 months before screening
• Received kidney transplant, or plan to receive kidney transplant during the trial